Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2020

01-04-2020 | NSCLC | Author Correction

Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

Authors: A. Passaro, P. Mancuso, S. Gandini, G. Spitaleri, V. Labanca, E. Guerini-Rocco, M. Barberis, C. Catania, E. Del Signore, F. de Marinis, F. Bertolini

Published in: Clinical and Translational Oncology | Issue 4/2020

Login to get access

Excerpt

Acknowledgements section was missing in the original published version. The Acknowledgement section read as follows: …
Metadata
Title
Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
Authors
A. Passaro
P. Mancuso
S. Gandini
G. Spitaleri
V. Labanca
E. Guerini-Rocco
M. Barberis
C. Catania
E. Del Signore
F. de Marinis
F. Bertolini
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 4/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02198-5

Other articles of this Issue 4/2020

Clinical and Translational Oncology 4/2020 Go to the issue

Research Article

Red and processed meat consumption and esophageal cancer risk: a systematic review and meta-analysis

Research Article

Human colorectal cancer derived-MSCs promote tumor cells escape from senescence via P53/P21 pathway

Research Article

The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients

Review Article

Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy

Review Article

Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients

Research Article

ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits